A case series analysis on the clinical experience of Impella 5.5® at a large tertiary care centre.

In this early experience of the pVAD 5.5, procedural and device-related complications were observed but were manageable, and overall survival was high in this critically ill cohort, particularly when the device was used as a bridge to other therapies.